Lupin has entered into an exclusive license, supply and distribution agreement with Gan & Lee Pharmaceuticals, headquartered in China, for a novel fortnightly GLP-1 receptor agonist, Bofanglutide. The agreement strengthens the company’s diabetes portfolio and accelerates its presence in the obesity segment. Bofanglutide injection is a fortnightly (once in two weeks) GLP-1 receptor agonist developed by Gan & Lee, intended for treating adults with type 2 diabetes and aiding weight management in overweight or obese individuals.
As a potential first-in-class global fortnightly GLP-1 agonist, clinical data demonstrate that the weight loss results of Bofanglutide are comparable to or better than those of existing GLP-1 alternatives while offering the convenience of once in two weeks versus once a week for other injectable alternatives, and maintaining safety and tolerability consistent with the GLP-1 class. It effectively reduces both blood glucose levels and body weight. Under the terms of the agreement, the company will have exclusive rights to commercialize and distribute Bofanglutide in India.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
